Effects of beta-endorphin2-9 on arginine-8-vasopressin and oxytocin levels in hypothalamic and limbic brain regions.
Immunoreactive arginine-8-vasopressin (AVP) and oxytocin (OXT) were measured in rat hypothalamic and limbic brain regions after the intracerebroventricular administration of beta-endorphin fragment 2-9 (beta E2-9). The peptide decreased the AVP content of the hippocampus and the OXT levels in the septum and amygdala. The present data favor the view that beta E2-9 interacts with limbic AVP- and OXT-systems.
D000679:Amygdala / Q000187:drug effects / Q000378:metabolism; D000818:Animals; D001127:Arginine Vasopressin / Q000378:metabolism*; D004723:Endorphins / Q000494:pharmacology*; D006624:Hippocampus / Q000187:drug effects / Q000378:metabolism; D007031:Hypothalamus / Q000187:drug effects / Q000378:metabolism*; D008032:Limbic System / Q000187:drug effects / Q000378:metabolism*; D008297:Male; D010121:Oxytocin / Q000378:metabolism*; D010446:Peptide Fragments / Q000494:pharmacology*; D051381:Rats; D011919:Rats, Inbred Strains; D012688:Septum Pellucidum / Q000187:drug effects / Q000378:metabolism; D001615:beta-Endorphin
D004723:Endorphins; D010446:Peptide Fragments; D001127:Arginine Vasopressin; D010121:Oxytocin; D001615:beta-Endorphin; C036560:beta-endorphin (2-9)